3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
10
Phase NA
4
Phase 2
4
Phase 1/2
4
Phase 4
2
Phase 3
2
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mastocytosis
1
Liver Neoplasms
1
Gastroenteropancreatic Neuroendocrine Tumors
1
GATA2 Deficiency
1
Colorectal Neoplasms
1
Advanced Solid Tumor
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
Standard of Care
3
Oxaliplatin
3
Melatonin
3
Gemcitabine
3
Fluorouracil
3
Drug Therapy
3
Ciprofloxacin
3
Capecitabine
3
pertuzumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
alectinib
2
Water
2
Vemurafenib
2
Trastuzumab
2
Sirolimus
2
Saline Solution
2
Pemetrexed
2
Methylphenidate
2
Lidocaine
2
Leucovorin
2
Immunoglobulins, Intravenous
2
Docetaxel
2
Dexmedetomidine
2
Cisplatin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasms
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled